At an inclusion rate of 37 ppm LEO, this formulation showed a significant reduction of in vitro CP proliferation as well as reduction of the harmful effects induced by the infection/dysbiosis of the NE model compared with the positive challenge control group. The gene discussed is CP; the disease is infection.